Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizotinib + Pembrolizumab in Untreated ALK+ NSCLC
NCT02511184Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Oct 2015
- Primary completion
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of crizotinib and pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Dose-limiting Toxicity at 6 weeks. Started Oct 2015; status: terminated.
02
Drugs
crizotinibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02511184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02511184.